|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024623,
umls-concept:C0332148,
umls-concept:C0449432,
umls-concept:C1155748,
umls-concept:C1179435,
umls-concept:C1334536,
umls-concept:C1416959,
umls-concept:C1514474,
umls-concept:C1524073,
umls-concept:C1548799,
umls-concept:C1554080,
umls-concept:C1705248,
umls-concept:C1706198,
umls-concept:C1708842
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-22
|
|
pubmed:abstractText |
We studied the subcellular localization of MAD2 in normal human tissues and gastric cancers. MAD2 showed nuclear and cytoplasmic localization in normal tissues such as muscle, testis, thyroid gland, cerebrum, trachea, and skin; blood vessels in some organs were also MAD2+. In normal stomach, MAD2 was expressed mainly in cytoplasm but showed nuclear staining in the majority of gastric cancers. MAD2 was significantly overexpressed in gastric cancer compared with matched adjacent tissues (P < .001), and expression was related to differentiation and other clinical parameters of cancer (P < .001). The cancer/adjacent normal tissue (C/N) ratio of MAD2 expression was higher than 2 and more frequently observed in patients with lymph gland metastasis (P < .05) and related to cancer differentiation. Our findings suggest that the steady-state amount of MAD2 inside cells may serve as a molecular switch in mitotic checkpoint control and that the subcellular localizations of this spindle protein undergo a shift during malignant transformation. The change of MAD2 expression may be involved mainly in gastric carcinogenesis and associated with the prognosis of gastric cancer; a C/N of more than 2 may be associated with the worse prognosis for survival in gastric carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1943-7722
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
131
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
793-801
|
|
pubmed:meshHeading |
pubmed-meshheading:19461085-Aged,
pubmed-meshheading:19461085-Blotting, Western,
pubmed-meshheading:19461085-Calcium-Binding Proteins,
pubmed-meshheading:19461085-Cell Cycle Proteins,
pubmed-meshheading:19461085-Cell Nucleus,
pubmed-meshheading:19461085-Cytoplasm,
pubmed-meshheading:19461085-Female,
pubmed-meshheading:19461085-Humans,
pubmed-meshheading:19461085-Immunohistochemistry,
pubmed-meshheading:19461085-Male,
pubmed-meshheading:19461085-Middle Aged,
pubmed-meshheading:19461085-Mitosis,
pubmed-meshheading:19461085-Prognosis,
pubmed-meshheading:19461085-Repressor Proteins,
pubmed-meshheading:19461085-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19461085-Stomach Neoplasms,
pubmed-meshheading:19461085-Tissue Array Analysis,
pubmed-meshheading:19461085-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
MAD2 as a key component of mitotic checkpoint: A probable prognostic factor for gastric cancer.
|
|
pubmed:affiliation |
Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
